Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Omarigliptin (Phase A)
Total, all-cause mortality	Placebo to Omarigliptin (Phase A)
Total, all-cause mortality	Omarigliptin (Phase A) → Omarigliptin (Phase B)
Total, all-cause mortality	Placebo to Omarigliptin (Phase A) → Glipizide (Phase B)
Total, other adverse events	Omarigliptin (Phase A)	24	106
Total, other adverse events	Placebo to Omarigliptin (Phase A)	25	106
Total, other adverse events	Omarigliptin (Phase A) → Omarigliptin (Phase B)	44	106
Total, other adverse events	Placebo to Omarigliptin (Phase A) → Glipizide (Phase B)	52	106
Total, serious adverse events	Omarigliptin (Phase A)	10	106
Total, serious adverse events	Placebo to Omarigliptin (Phase A)	13	106
Total, serious adverse events	Omarigliptin (Phase A) → Omarigliptin (Phase B)	22	106
Total, serious adverse events	Placebo to Omarigliptin (Phase A) → Glipizide (Phase B)	22	106

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01698775/event-totals